Our survey asked 443 adults for a gut reaction to the idea of treating depression or PTSD with ketamine. The biggest share, 34 percent, went with cautious but open. Next came skeptical at 21 percent. Hopeful or curious and never heard of it tied at 18 percent apiece, while 9 percent reacted negatively.

Skepticism is a fair default for medical claims. The trouble is that much of the doubt in this category is aimed at things that are not accurate in the first place, so people reject a treatment that does not exist and never weigh the one that does. Here is what the record says, and what it does not.

Belief one: this is a fringe treatment with no official standing

Esketamine, brand name Spravato, carries Food and Drug Administration approval for treatment-resistant depression. A separate approval covers adults with major depression during an acute suicidal crisis. Patients use it together with an oral antidepressant, and it is distributed through a restricted program to certified sites only.

Approval does not promise that any single patient will improve, and it does not mean the drug suits everyone. It does mean the treatment sits inside the regulated system.

That matters to patients, not only to regulators. Among our respondents, FDA approval would settle the question or count heavily for 59 percent; just 14 percent told us it would not matter to them at all.

Belief two: ketamine and esketamine are the same product

They are related, and they are not interchangeable. The approved nasal spray is one thing. IV ketamine for depression at an infusion clinic uses an approved anesthetic off label, meaning for a purpose the approval does not cover. Ketamine shipped to your house by a telehealth prescriber is a third arrangement with the least supervision of the three.

Different approval status, settings, monitoring, evidence, and bills. Anyone who treats them as one product is careless or counting on you not to notice.

Belief three: you take it at home like any other prescription

Not the approved spray. You take each dose at a certified site with a health professional present, you stay for a monitoring period, and you do not drive yourself home. That monitoring exists because of known effects during sessions, including dissociation and higher blood pressure. If you want a concrete picture of a session, Brain Recovery Centers lays out what happens during Spravato treatment step by step.

People have opinions about that burden. In our poll, the in-person clinic was preferred by 44 percent. Telehealth from home was the pick of 22 percent, a clinic start with care later shifted home took 23 percent, and the other 11 percent had no view. Preference and the rules of an approved treatment are different things, and a clinician should walk you through the gap.

Belief four: it is a party drug repackaged for profit

Ketamine has a history of recreational misuse, and that is not a smear. It is also on the World Health Organization's essential medicines list for anesthesia, and surgical teams have given it to adults and children for decades.

Both are true at once, which is ordinary in medicine. The real questions are the usual ones: what dose, what setting, who supervises, what monitoring, which diagnosis. A treatment answers them. A misuse pattern does not.

Belief five: it is a last resort for people who are beyond help

What it was approved for, depression that has outlasted two or more fair antidepressant trials, is a routine clinical situation, not the far edge of human suffering.

Our survey gives a sense of how routine. Depression, anxiety, or PTSD that standard prescriptions did not fix had touched 72 percent of the people who answered, either directly or through someone close. Thirty-seven percent meant themselves, 22 percent meant someone in their circle, and 13 percent meant both. Just 28 percent reported nothing of the kind.

Calling nearly three quarters of a general sample beyond help is wrong and corrosive.

Belief six: if it were real, my doctor would have mentioned it

Of all six, this one is the easiest to sympathize with, and our data pushes back on it hardest. Spravato was a name 73 percent of our respondents had simply never come across. A further 21 percent recognized the word with nothing behind it, leaving 6 percent who could say what the drug is.

A visit is short and covers what is most urgent, and a restricted treatment is not offered in every town. Silence in fifteen minutes is weak evidence either way.

Transcranial magnetic stimulation, another option in this space, shows the same pattern in our results. Half of respondents, 51 percent, could not have told you what TMS stood for, yet they cared that a treatment could work without medicine, while 25 percent were unfamiliar with it and indifferent to that feature. Thirteen percent knew TMS and cared a lot about the drug-free part; 12 percent knew it and said that changed little. About a quarter knew the option existed, while nearly two thirds valued what it offers. Unfamiliarity, not opposition, defines this landscape.

What honest skepticism looks like

None of this argues that you should want this treatment. There are real reasons for caution: side effects during sessions, the time cost of monitored visits, uneven quality among clinics rushing into a growing market, and the plain fact that no psychiatric treatment works for everyone.

Useful skepticism asks whether a clinic wants records of your past treatment, who supervises the session, what happens if something goes wrong, and what insurance will pay. Unhelpful skepticism rejects a category nobody has described to you accurately.

Nothing here is medical advice, and whether a treatment fits your history is for a clinician who can read your record. Your job is only to make sure the thing you accept or reject is the real one.

If suicide has been on your mind, please do not carry that alone today. Dial or text 988, wherever you are in the U.S., and the Suicide and Crisis Lifeline picks up. It is private, it costs nothing, and someone is on shift at every hour.

Methodology

These results come from our own survey; the publisher paid for it and commissioned it. Pollfish fielded it to its consumer panel, and 443 adults, all between 18 and 64 and all from the Midwest, finished it by the June 23, 2026 close, each after consenting. Ten states were represented. Where people could check more than one answer, the shares total more than 100. No number here predates the panel's final validation.